232 related articles for article (PubMed ID: 12767082)
1. Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: a prognostic marker for good clinical outcome in human breast carcinoma.
Span PN; Sweep CG; Manders P; Beex LV; Leppert D; Lindberg RL
Cancer; 2003 Jun; 97(11):2710-5. PubMed ID: 12767082
[TBL] [Abstract][Full Text] [Related]
2. Low expression of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) indicates a shorter survival after resection in patients with adenocarcinoma of the lung.
Takemoto N; Tada M; Hida Y; Asano T; Cheng S; Kuramae T; Hamada J; Miyamoto M; Kondo S; Moriuchi T
Lung Cancer; 2007 Dec; 58(3):376-83. PubMed ID: 17714826
[TBL] [Abstract][Full Text] [Related]
3. Expression of membrane-anchored matrix metalloproteinase inhibitor reversion inducing cysteine rich protein with Kazal motifs in murine cell lines.
Takagi S; Hoshino Y; Osaki T; Okumura M; Fuginaga T
Exp Oncol; 2007 Mar; 29(1):30-4. PubMed ID: 17431385
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological significance of the gene expression of matrix metalloproteinases and reversion-inducing cysteine-rich protein with Kazal motifs in patients with colorectal cancer: MMP-2 gene expression is a useful predictor of liver metastasis from colorectal cancer.
Oshima T; Kunisaki C; Yoshihara K; Yamada R; Yamamoto N; Sato T; Makino H; Yamagishi S; Nagano Y; Fujii S; Shiozawa M; Akaike M; Wada N; Rino Y; Masuda M; Tanaka K; Imada T
Oncol Rep; 2008 May; 19(5):1285-91. PubMed ID: 18425389
[TBL] [Abstract][Full Text] [Related]
5. Prognostic values of matrix metalloproteinase family expression in human colorectal carcinoma.
Asano T; Tada M; Cheng S; Takemoto N; Kuramae T; Abe M; Takahashi O; Miyamoto M; Hamada J; Moriuchi T; Kondo S
J Surg Res; 2008 May; 146(1):32-42. PubMed ID: 17543340
[TBL] [Abstract][Full Text] [Related]
6. The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer.
Takeuchi T; Hisanaga M; Nagao M; Ikeda N; Fujii H; Koyama F; Mukogawa T; Matsumoto H; Kondo S; Takahashi C; Noda M; Nakajima Y
Clin Cancer Res; 2004 Aug; 10(16):5572-9. PubMed ID: 15328199
[TBL] [Abstract][Full Text] [Related]
7. High MMP-1 mRNA expression is a risk factor for disease-free and overall survivals in patients with invasive breast carcinoma.
Cheng S; Tada M; Hida Y; Asano T; Kuramae T; Takemoto N; Hamada J; Miyamoto M; Hirano S; Kondo S; Moriuchi T
J Surg Res; 2008 May; 146(1):104-9. PubMed ID: 17663001
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of reversion-inducing cysteine-rich protein with Kazal motifs expression in resected pathologic stage IIIA N2 non-small-cell lung cancer.
Takenaka K; Ishikawa S; Yanagihara K; Miyahara R; Hasegawa S; Otake Y; Morioka Y; Takahashi C; Noda M; Ito H; Wada H; Tanaka F
Ann Surg Oncol; 2005 Oct; 12(10):817-24. PubMed ID: 16132376
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase-9 activity is associated with poor prognosis in T3-T4 node-negative colorectal cancer.
Cho YB; Lee WY; Song SY; Shin HJ; Yun SH; Chun HK
Hum Pathol; 2007 Nov; 38(11):1603-10. PubMed ID: 17669467
[TBL] [Abstract][Full Text] [Related]
10. RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis.
Masui T; Doi R; Koshiba T; Fujimoto K; Tsuji S; Nakajima S; Koizumi M; Toyoda E; Tulachan S; Ito D; Kami K; Mori T; Wada M; Noda M; Imamura M
Clin Cancer Res; 2003 May; 9(5):1779-84. PubMed ID: 12738734
[TBL] [Abstract][Full Text] [Related]
11. Correlation of reversion-inducing cysteine-rich protein with kazal motifs (RECK) and extracellular matrix metalloproteinase inducer (EMMPRIN), with MMP-2, MMP-9, and survival in colorectal cancer.
van der Jagt MF; Sweep FC; Waas ET; Hendriks T; Ruers TJ; Merry AH; Wobbes T; Span PN
Cancer Lett; 2006 Jun; 237(2):289-97. PubMed ID: 16046057
[TBL] [Abstract][Full Text] [Related]
12. RECK gene expression in hepatocellular carcinoma: correlation with invasion-related clinicopathological factors and its clinical significance. Reverse-inducing--cysteine-rich protein with Kazal motifs.
Furumoto K; Arii S; Mori A; Furuyama H; Gorrin Rivas MJ; Nakao T; Isobe N; Murata T; Takahashi C; Noda M; Imamura M
Hepatology; 2001 Jan; 33(1):189-95. PubMed ID: 11124835
[TBL] [Abstract][Full Text] [Related]
13. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
[TBL] [Abstract][Full Text] [Related]
14. Expression and localisation of the new metalloproteinase inhibitor RECK (reversion inducing cysteine-rich protein with Kazal motifs) in inflamed synovial membranes of patients with rheumatoid arthritis.
van Lent PL; Span PN; Sloetjes AW; Radstake TR; van Lieshout AW; Heuvel JJ; Sweep CG; van den Berg WB
Ann Rheum Dis; 2005 Mar; 64(3):368-74. PubMed ID: 15485996
[TBL] [Abstract][Full Text] [Related]
15. RECK expression in osteosarcoma: correlation with matrix metalloproteinases activation and tumor invasiveness.
Kang HG; Kim HS; Kim KJ; Oh JH; Lee MR; Seol SM; Han I
J Orthop Res; 2007 May; 25(5):696-702. PubMed ID: 17262820
[TBL] [Abstract][Full Text] [Related]
16. Expression of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) as a prognostic indicator in gastric cancer.
Song SY; Son HJ; Nam E; Rhee JC; Park C
Eur J Cancer; 2006 Jan; 42(1):101-8. PubMed ID: 16324834
[TBL] [Abstract][Full Text] [Related]
17. Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer.
Takenaka K; Ishikawa S; Kawano Y; Yanagihara K; Miyahara R; Otake Y; Morioka Y; Takahashi C; Noda M; Wada H; Tanaka F
Eur J Cancer; 2004 Jul; 40(10):1617-23. PubMed ID: 15196549
[TBL] [Abstract][Full Text] [Related]
18. Expression of matrix metalloproteinase regulator, RECK, and its clinical significance in osteosarcoma.
Xu J; Wu S; Shi X
J Orthop Res; 2010 Dec; 28(12):1621-5. PubMed ID: 20973064
[TBL] [Abstract][Full Text] [Related]
19. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of the RECK-tumor and metastasis suppressor gene in glioma invasiveness.
Correa TC; Brohem CA; Winnischofer SM; da Silva Cardeal LB; Sasahara RM; Taboga SR; Sogayar MC; Maria-Engler SS
J Cell Biochem; 2006 Sep; 99(1):156-67. PubMed ID: 16791855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
